Supernus Pharmaceuticals Investor Relations Material
Latest events
Q2 2025
Supernus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Supernus Pharmaceuticals Inc
Access all reports
Supernus Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system (CNS) disorders. The company specializes in therapies for neurological and psychiatric conditions, including epilepsy, attention deficit hyperactivity disorder (ADHD), and depression. Supernus Pharmaceuticals Inc. is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.
Key slides for Supernus Pharmaceuticals Inc
Study Update
Supernus Pharmaceuticals Inc
Study Update
Supernus Pharmaceuticals Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SUPN
Country
🇺🇸 United States